const obj = [
  {
    pageContent:
      "1\nMS COVID-19 Briefing\n7 January 2021\nRecommendations on COVID-19 Vaccines\nWHO Scientific Advisory Group of Experts (SAGE)",
    metadata: {
      source: "uploads/3105-SAGE_COVID.pdf",
      pdf: {
        version: "1.10.100",
        info: {
          PDFFormatVersion: "1.6",
          IsAcroFormPresent: false,
          IsXFAPresent: false,
          Title: "PowerPoint Presentation",
          Author: "Bruce  Aylward",
          Creator: "Microsoft® PowerPoint® for Office 365",
          Producer: "Adobe PDF Library 20.13.106",
          CreationDate: "D:20210108104234+01'00'",
          ModDate: "D:20210108104235+01'00'",
        },
        metadata: {
          _metadata: {
            "xmp:modifydate": "2021-01-08T10:42:35+01:00",
            "xmp:createdate": "2021-01-08T10:42:34+01:00",
            "xmp:metadatadate": "2021-01-08T10:42:35+01:00",
            "xmp:creatortool": "Microsoft® PowerPoint® for Office 365",
            "xmpmm:documentid": "uuid:9b8b9e26-b20b-46f5-aab2-54c410972918",
            "xmpmm:instanceid": "uuid:4f4e4e76-c991-4197-9208-3b5ad9085f64",
            "dc:format": "application/pdf",
            "dc:title": "PowerPoint Presentation",
            "dc:creator": "Bruce  Aylward",
            "pdf:producer": "Adobe PDF Library 20.13.106",
            "pdfx:created": "05/08/2020 01:00:00",
            "pdfx:lastsaved": "05/08/2020 01:00:00",
            "pdfx:contenttypeid": "0x01010026D742755BFBB840A7DF641BA6176A3A",
          },
        },
        totalPages: 3,
      },
      loc: {
        pageNumber: 1,
      },
    },
  },
  {
    pageContent:
      "2\nWHO interim recommendation for the use of mRNA BNT162b2 \n(Pfizer-BioNTech) (1/2)\n•BNT162b2 (Pfizer vaccine) has been shown to have an efficacyof 95% against \nsymptomatic SARS-CoV-2 infection.\n•No data are available related to impact on transmission or viral shedding.\n•Vaccination is recommended for persons aged 16 years and above.\n•The recommended schedule is two doses given intramuscularly with an interval \nof 21–28 days between the doses.\n•The need for flexibilityin the schedule was acknowledged and current data \nsupport an extension up to 42 days (6 weeks).\n•The same product should be used for both doses. There are no studies on\ninterchangeabilitywith other vaccines against COVID-19 .",
    metadata: {
      source: "uploads/3105-SAGE_COVID.pdf",
      pdf: {
        version: "1.10.100",
        info: {
          PDFFormatVersion: "1.6",
          IsAcroFormPresent: false,
          IsXFAPresent: false,
          Title: "PowerPoint Presentation",
          Author: "Bruce  Aylward",
          Creator: "Microsoft® PowerPoint® for Office 365",
          Producer: "Adobe PDF Library 20.13.106",
          CreationDate: "D:20210108104234+01'00'",
          ModDate: "D:20210108104235+01'00'",
        },
        metadata: {
          _metadata: {
            "xmp:modifydate": "2021-01-08T10:42:35+01:00",
            "xmp:createdate": "2021-01-08T10:42:34+01:00",
            "xmp:metadatadate": "2021-01-08T10:42:35+01:00",
            "xmp:creatortool": "Microsoft® PowerPoint® for Office 365",
            "xmpmm:documentid": "uuid:9b8b9e26-b20b-46f5-aab2-54c410972918",
            "xmpmm:instanceid": "uuid:4f4e4e76-c991-4197-9208-3b5ad9085f64",
            "dc:format": "application/pdf",
            "dc:title": "PowerPoint Presentation",
            "dc:creator": "Bruce  Aylward",
            "pdf:producer": "Adobe PDF Library 20.13.106",
            "pdfx:created": "05/08/2020 01:00:00",
            "pdfx:lastsaved": "05/08/2020 01:00:00",
            "pdfx:contenttypeid": "0x01010026D742755BFBB840A7DF641BA6176A3A",
          },
        },
        totalPages: 3,
      },
      loc: {
        pageNumber: 2,
      },
    },
  },
  {
    pageContent:
      "3\nWHO interim recommendation for the use of mRNA BNT162b2 \n(Pfizer-BioNTech) (2/2): Vaccination of specific populations\n•BNT162b2 is not a live vaccine, the mRNA does not enter the nucleus and \nis rapidly degraded. Animal studies show no toxicity to the fetus, but no \ndata on safety in pregnant women exist. \n•SAGE recommends not to use BNT162b2 in pregnancyuntil more data \nare available, except where the benefit outweighs risks, such as health \nworkers at high risk of exposure or women with significant comorbidities.\n•Vaccination can be offered to breastfeeding women if part of risk group, \nand WHO does not recommend discontinuation of breastfeeding after \nvaccination.\n•Vaccination can be offered to people living with HIV in accordance to the \nprioritization roadmap",
    metadata: {
      source: "uploads/3105-SAGE_COVID.pdf",
      pdf: {
        version: "1.10.100",
        info: {
          PDFFormatVersion: "1.6",
          IsAcroFormPresent: false,
          IsXFAPresent: false,
          Title: "PowerPoint Presentation",
          Author: "Bruce  Aylward",
          Creator: "Microsoft® PowerPoint® for Office 365",
          Producer: "Adobe PDF Library 20.13.106",
          CreationDate: "D:20210108104234+01'00'",
          ModDate: "D:20210108104235+01'00'",
        },
        metadata: {
          _metadata: {
            "xmp:modifydate": "2021-01-08T10:42:35+01:00",
            "xmp:createdate": "2021-01-08T10:42:34+01:00",
            "xmp:metadatadate": "2021-01-08T10:42:35+01:00",
            "xmp:creatortool": "Microsoft® PowerPoint® for Office 365",
            "xmpmm:documentid": "uuid:9b8b9e26-b20b-46f5-aab2-54c410972918",
            "xmpmm:instanceid": "uuid:4f4e4e76-c991-4197-9208-3b5ad9085f64",
            "dc:format": "application/pdf",
            "dc:title": "PowerPoint Presentation",
            "dc:creator": "Bruce  Aylward",
            "pdf:producer": "Adobe PDF Library 20.13.106",
            "pdfx:created": "05/08/2020 01:00:00",
            "pdfx:lastsaved": "05/08/2020 01:00:00",
            "pdfx:contenttypeid": "0x01010026D742755BFBB840A7DF641BA6176A3A",
          },
        },
        totalPages: 3,
      },
      loc: {
        pageNumber: 3,
      },
    },
  },
];
